Buy Rating for Liquidia Technologies Driven by FDA Approval and Strategic Launch of Yutrepia

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), boosting the price target to $41.00.

Cory Jubinville, PhD has given his Buy rating due to a combination of factors, primarily focusing on the recent FDA approval of Liquidia Technologies’ Yutrepia for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). The approval has positioned Liquidia to launch Yutrepia with a strategic pricing plan that matches its competitor, Tyvaso DPI, and an initial rollout supported by a dedicated sales force targeting key specialty centers and community practices.
Liquidia’s proprietary PRINT technology, which enhances drug delivery, along with patient support programs, is expected to facilitate early adoption of Yutrepia. The company’s focus on providing early patient access is anticipated to drive significant uptake over the next few quarters, serving as a crucial indicator of commercial success. These strategic initiatives, combined with the potential for broad coverage by early 2026, have led to an updated price target of $41 per share, underpinning the Buy rating.

According to TipRanks, Jubinville, PhD is an analyst with an average return of -15.1% and a 27.06% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Mereo Biopharma Group Plc, and Tenaya Therapeutics.

In another report released today, Scotiabank also maintained a Buy rating on the stock with a $37.00 price target.